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Purpose
Current chemotherapeutics for treating locally advanced or metastatic soft tissue sarcomas
(STS) are limited. Accordingly, the present in vitro study was conducted to evaluate the
effects of treatment of STS cells with tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) applied as a single agent or in combination with a proteasome inhibitor, MG132.
Materials and Methods
Sensitivity to TRAIL and activity of TRAIL-induced apoptotic pathways were analyzed in four
STS cell lines: HTB-82 (rhabdomyosarcoma), HT-1080 (fibrosarcoma), HTB-93 (synovial
sarcoma), and HTB-94 (chondrosarcoma). Reduction of the dye dimethylthiazolyl 2,5
diphenyltetrazolium bromide (MTT) was used to evaluate cytotoxic activity; western blots
were used to evaluate TRAIL-induced apoptosis.
Results
TRAIL induced apoptosis in HTB-93 cells, but had little effect in HTB-82, HT-1080, or HTB-94
cells. Expression of TRAIL receptor-1 and -2 did not correlate with sensitivity to TRAIL. Co-
incubation of cells with TRAIL and a proteasome inhibitor, MG132, augmented the apoptotic
effect of TRAIL in both TRAIL-sensitive and TRAIL-resistant cells. This effect was due to up-
regulation of TRAIL receptors and members of the pro-apoptotic BCL-2 family by MG132.
Conclusion
These data show that combining TRAIL with MG132 enhances apoptosis and overcomes
TRAIL resistance. This restoration of TRAIL sensitivity occurs through an increase in the ex-
pression of death receptor 5 and of pro-apoptotic BCL-2 family members such as BAX. 
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Introduction
Locally advanced sarcomas are tumors that invade nerves, vessels,
and joints, or extra-compartmental extensions of tumors that infiltrate
other surrounding structures. Although a variety of therapeutic
modalities for treatment of locally advanced soft tissue sarcomas (STS)
are available, including radiotherapy, chemotherapy, combined
chemotherapy and radiotherapy (with and without regional hy-
perthermia), and isolated limb perfusion [1], the efficacy of clinically
available chemotherapeutic agents in STS is limited [2]. 
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand
(TRAIL), a type II transmembrane protein that exhibits sequence
homology to TNF-ǯand FasL, induces apoptosis in a variety ofHee-Jeong Cheong, et al_Proteasome Inhibitor Augments TRAIL-Induced Apoptosis 
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transformed or cancer cells but not in normal cells [3]. TRAIL
modulates the apoptotic response by binding to receptors, including the
death receptor 4 (DR4, TRAIL-R1) [4], KILLER/DR5 (TRAIL-R2)
[5], TRID (DcR1, TRAIL-R3) [6], TRUNDD (DcR2, TRAIL-R4) [7],
and osteoprotegerin (OPG) [8]. Both DR4 and DR5 have a C-terminal
death domain that signals through downstream caspase activation. In
contrast, TRAIL-R3 and TRAIL-R4 lack a functional cytoplasmic
death domain. These two receptors serve as decoys, protecting cells
from TRAIL-induced apoptosis by competing with death-inducing
TRAIL receptors for TRAIL binding [9]. OPG binds TRAIL, but has
lower affinity at physiological temperature [10]. Despite considerable
interest in the potential of TRAIL in novel anticancer therapies, many
tumor cell lines are partially or completely resistant to this agent when
used alone [11,12]. Hence, a great deal of research has focused on
improving the potency of TRAIL-based therapeutic approaches, some
by establishing new modalities for combined treatment with TRAIL
and other agents.
The proteasome is a multi-catalytic proteinase complex responsible
for ubiquitin-mediated protein degradation and maintenance of
homeostasis in eukaryotic cells. This complex is primarily involved in
the degradation of misfolded and short-lived regulatory proteins
essential for cell cycle progression, apoptosis, and signal transduction.
Malignant cells, which frequently contain mutations in cell cycle and
apoptotic checkpoint proteins responsible for tumorigenesis, are more
susceptible to certain proteasome inhibitors [13]. Recent reports have
demonstrated that a variety of tumor cell types can be sensitized to
TRAIL-induced apoptosis by combining TRAIL with proteasome
inhibitors such as bortezomib [14,15]. 
In the present study, we investigated susceptibility to TRAIL in STS
cell lines of various origins, and examined the efficacy of combination
therapy with TRAIL and the proteasome inhibitor MG132. 
Materials and Methods
1 STS cell lines
Human HTB-82 (rhabdomyosarcoma), HTB-93 (synovial sarco-
ma), and HTB-94 (chondrosarcoma) cell lines were obtained from the
American Type Culture Collection (ATCC, Rockville, MD). The
human HT-1080 (fibrosarcoma) cell line was obtained from the
Korean Cell Line Bank (Seoul, Korea). HTB-93 and HTB-94 cell lines
were cultured in Leibovitz’s L-15 medium; the HTB-82 cell line was
cultured in modified McCoy’s 5a Medium; the HT-1080 cell line was
cultured in RPMI 1640 medium with 10% heat-inactivated fetal calf
serum (WelGENE Inc., Seoul, Korea), 50 U/mL penicillin and 50 Ǻ g/
mL streptomycin. 
2 Measurement of cell viability 
Cell viability was assessed by dimethylthiazolyl-2,5-diphenyltetra-
zolium bromide (MTT) assay using a cell proliferation kit (Roche,
Roche Diagnostics GmbH, Mannheim, Germany). In this assay, the
membrane permeable tetrazolium dye is reduced by mitochondrial
reductase in living cells to an insoluble form that is dissolved in deter-
gent and measured spectrophotometrically to identify and quantify
viable cells. Equal numbers of cells (510
4) of each of the four dif-
ferent STS cell lines were cultured in wells of a 96-well plate at 37
for 24 hours. Cells were treated with 10 and 20 ng/mL of TRAIL
(R&D Co., Minneapolis, MN); 1, 2, and 10 Ǻ M of MG132 (Calbio-
chem, Darmstadt, Germany); or a combination of TRAIL and MG132.
After culturing with TRAIL and/or MG132 at 37for 24 hours, 10 Ǻ L
of MTT labeling reagent was added to each well. Four hours later, 100
Ǻ L of a solubilization solution was added to dissolve the formazan
crystals. The absorbance was measured using an enzyme-linked
immunosorbent assay plate reader at a wavelength of 562 nm. 
3 Western blot analysis 
For western blot analyses, cells were lysed in ice-cold phosphate-
buffered saline (PBS) containing 1% Nonidet P 40, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 2.0 Ǻ g/mL apro-
tinin and protease inhibitor cocktail II (Sigma-Aldrich, St. Louis, MO).
The lysed cells were centrifuged at 12,000 rpm to remove cellular
debris. The protein concentration in the extracts was determined by co-
lorimetric bicinchoninic acid analysis (Micro BCA protein assay re-
agent kit, Pierce, Rockford, IL). Proteins (40 Ǻ g total) were separated
by SDS-polyacrylamide gel electrophoresis on a 10% gel, and than elec-
trophoretically transferred to a polyvinylidene difluoride membrane
(Bio-Rad Laboratories, Hercules, CA). The membrane was blocked in
TTBS (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% v/v Tween 20)
containing 5% nonfat dry milk (TTBS/5% milk) for 1 hour at room
temperature, and then incubated for 4 hours at room temperature with
primary antibodies diluted 1 : 1,000 in TTBS/5% milk. DR4, DR5
(ProSci Inc., Poway, CA), BID and BAX (Santa Cruz Inc., Santa Cruz,
CA) were detected using rabbit polyclonal antibodies; caspase-3,
caspase-8 (Assay Designs, Inc., Victoria, BC, Canada) and Fas
associated death domain (FADD, BD Pharmingen, Franklin Lakes,
NJ) were detected using mouse monoclonal antibodies. After washing
the membrane three times with TTBS for 15 minutes, the membrane
was incubated for 1 hour at room temperature with horseradish
peroxidase-conjugated secondary immunoglobulins (Dako, Glostrup,
Denmark) diluted 1 : 3,000 with TTBS/5% milk. The membrane was
then washed three times as described above, and developed using an
enhanced chemiluminescence detection system (Amersham Corp.,
Buckinghamshire, UK).Cancer Res Treat. 2011;43(2):124-130
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4 Measurement of surface expression of TRAIL receptors 
After 24 hours treatment with MG132, cells were harvested with
0.05% trypsin-EDTA and washed twice with isotonic PBS. Cells (2
10
6) were incubated with phycoerythrin (PE) anti-human DR4
(TRAIL-R1, CD261) and PE anti-human DR5 (TRAIL-R2, CD262)
antibodies (20 Ǻ L; BioLegend, San Diego, CA) for 45 minutes at 4.
After washing, 110
5 cells were analyzed using a FACSVantage SE
Flow Cytometer (BD Pharmingen, Franklin Lakes, NJ). Data analysis
was conducted using Cell Quest software (BD Pharmigen). 
5 Statistical analysis
Data are expressed as means±standard error of the means calculated
from three separate experiments, each performed in triplicate.
Statistical significance of differences between two groups was
determined using the paired two-tailed Student’s t-test.
Results
1 Cytotoxic effects of TRAIL and MG132 in STS cell lines
To assess possible cytotoxic effects of TRAIL on STS cells, we
tested the viability of four STS cell lines, by MTT assay, after
treatment with TRAIL. TRAIL sensitivity was defined as a reduction
in cell viability to less than 75% that of controls after a 24 hours in-
cubation with TRAIL. The four STS cell lines were variably sensitive
to TRAIL. In the HTB-93 cell line, a 24 hours incubation with TRAIL
(10 or 20 ng/mL) showed cell viability decreases as a function of in-
creasing TRAIL concentration (pģ0.05); in contrast, HTB-82, HT-
1080, and HTB-94 cells were resistant to TRAIL (Fig. 1A). In all four
cell lines, MG132 alone (1-10 Ǻ M) induced a dose-dependent re-
duction in cell viability after 24 hours of incubation. However,
sensitivity varied among cell lines, with ģ2 Ǻ M of MG132 signi-
ficantly decreasing cell viability (pģ0.05) in HTB-93 and HTB-94
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Fig. 1.  Cell viability of soft tissue sarcomas (STS) cell lines treated
with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL),
MG132 and a combination of both agents. (A, B) Cells were incu-
bated for 24 hr in the presence of different concentrations of TRAIL
and/or MG132. pģ0.05, compared to control or lower dose of each
treatment. Cell viability was quantified by MTT assay; each treatment
was performed in triplicate. (C) Adding MG132 to TRAIL augmented
the apoptosis compared to exposure to a single agent, TRAIL or
MG132, in TRAIL-sensitive cells (HTB-93) and TRAIL-resistant
cells (HTB-82, HT-1080, and HTB-94). pģ0.05, compared to
TRAIL 10 ng/mL, MG132 1 Ǻ M, and MG132 2 Ǻ M. (T10/M1: 10
ng/mL TRAIL+1 Ǻ M MG132; T10/M2: 10 ng/mL TRAIL+2 Ǻ M
MG132).Hee-Jeong Cheong, et al_Proteasome Inhibitor Augments TRAIL-Induced Apoptosis 
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2 Enhancement of TRAIL-induced apoptosis in STS
cell lines by co-treatment with the proteasome
inhibitor, MG132
To determine whether combining TRAIL with MG132 sensitized
STS cells to TRAIL-induced apoptosis, we exposed TRAIL-sensitive
and TRAIL-resistant STS cell lines to different concentrations of
MG132 (1 or 2 Ǻ M) in the presence or absence of a fixed concentration
of TRAIL (10 ng/mL) for 24 hours. The results showed a significant
decrease in viability in all four lines of STS cells treated with a
combination of TRAIL and MG132 compared with either agent alone
(pģ0.05) (Fig. 1C), demonstrating that MG132 restores TRAIL sen-
sitivity to TRAIL-resistant STS cells. 
3 Detection of apoptosis 
We next investigated whether the decrease in STS cell viability
observed using a combination of TRAIL and MG132 was attributable
to apoptosis. Because stimuli that trigger apoptosis all appear to act
through caspase activation, we evaluated the effects of 24-hour treat-
ment with TRAIL and/or MG132 in STS cells pre-incubated for 1
hour with or without the broad-spectrum irreversible caspase inhibitor,
z-VAD-fmk. MTT assays showed that cell death induced by the com-
bination of TRAIL and MG132 was markedly reduced in all cell lines
by z-VAD-fmk (20 Ǻ M). In contrast, a caspase-8 inhibitor, z-IETD-
fmk, had less striking effects on cell death elicited by the combination
of TRAIL and MG132 in the four STS cell lines (Fig. 2A and B).
These results indicate that enhanced cell death is caspase-dependent
and imply an apoptotic mechanism. This latter interpretation was
confirmed by terminal transferase-mediated dUTP nick-end labeling
staining using the in situ cell death detection kit (Chemicon, Temecula,
CA) according to the manufacturer’s protocol, which detects a
characteristic stain in apoptotic cells (data not shown).
4 Expression of apoptotic proteins and sensitivity to TRAIL
Because TRAIL mostly induces apoptosis directly via the FADD
caspase-8 dependent signaling pathway [9], the variable sensitivity of
STS cell lines to TRAIL could reflect variable expression of death
receptors and signal pathway molecules. To assess this possibility, we
measured protein levels of receptors and signaling pathway
components by western blotting. Of the five TRAIL receptors, two
(DR4 and DR5) are involved in caspase activation; the remaining
TRAIL receptors, TRAIL-R3, TRAIL-R4, and OPG, are not. We
found that DR4 was expressed in TRAIL-sensitive HTB-93 cells but
not in TRAIL-resistant HT-1080 and HTB-94 cells, consistent with the
idea that TRAIL sensitivity is correlated with expression of TRAIL
receptors involved in caspase activation. However, this observation
was not confirmed in HTB-82 cells, which, despite being TRAIL-
resistant, expressed both DR4 and DR5 receptors, suggesting that the
mechanism of resistance was different in these cells. In addition, DR5
was expressed in both TRAIL-sensitive (HTB-93) and TRAIL-
resistant (HTB-82, HT-1080, and HTB-94) cells, indicating that DR5
expression is not correlated with TRAIL sensitivity in STS cell lines
(Fig. 3A). Thus, differences in TRAIL sensitivity among the different
STS cell lines could not be distinguished on the basis of expression of
the TRAIL receptors DR4 and DR5. In addition, FADD/caspase-8
signal pathway molecules were expressed in the four different STS
cells; thus, TRAIL resistance was not attributable to the absence of









































Fig. 2. Evaluation of apoptosis. The broad-spectrum caspase inhibitor z-VAD-fmk or the caspase-8 inhibitor z-IETD-fmk was applied for 1 hr
before treatment of soft tissue sarcomas (STS) cells with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and MG132 for 24 hr.
(A, B) The decrease in cell viability induced by combined treatment with MG132 and TRAIL and measured by MTT assay was caspase
dependent. Similar results were obtained in three separate experiments. pģ0.05 compared to the combination of TRAIL and MG132.Cancer Res Treat. 2011;43(2):124-130
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Fig. 3. Expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors and apoptotic molecules in soft tissue sarcomas
(STS) cells. (A) After incubating each of the four STS cell lines for 24 hr with different concentrations of MG132, expression levels of TRAIL re-
ceptors and apoptotic molecules were determined by western blot analysis. (B) Analysis of the surface expression of death receptor (DR)4 and
DR5 was determined by flow cytometry in HT-1080 and HTB-82 cells. C, control; M1, 1 Ǻ M MG132; M2, 2 Ǻ M MG132; M10, 10 Ǻ M MG132.Hee-Jeong Cheong, et al_Proteasome Inhibitor Augments TRAIL-Induced Apoptosis 
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5 Changes in the expression of TRAIL receptors and
downstream apoptosis pathway components induced
by MG132 
To identify the mechanism by which combined treatment with
MG132 and TRAIL restores sensitivity to TRAIL-induced apoptosis,
we investigated changes in TRAIL receptors and receptor signaling
molecules after treatment with MG132. Western blot analyses showed
that treatment with different concentrations of MG132 for 24 hours
variably affected TRAIL receptor expression in the four cell lines. DR4
expression was increased in HTB 82 (TRAIL-resistant) and HTB-93
(TRAIL-sensitive) cells; however, DR5 expression was elevated in all
four STS cells (Fig. 3A). 
Using flow cytometry, we confirmed that these MG132-induced
changes in whole-cell TRAIL receptor expression are reflected in an
increase in the levels of DR4 and DR5 at the cell surface. These results
suggest that the reactivation of TRAIL sensitivity in TRAIL-resistant
cells by MG132 is related to an increase in the cell surface expression
of TRAIL receptors (Fig. 3B).
The binding of TRAIL to death receptors causes trimerization of the
death receptor, which recruits a specific adapter molecule, FADD,
leading to activation of the receptor-mediated pathway. Because
MG132 upregulated TRAIL receptor levels, we next tested whether
expression of downstream molecules, FADD, caspase-8, and caspase-
3, are affected by MG132. We found that MG132 induced an increase
in FADD in HTB-82, HTB-93, and HTB-94 cells, but not in HT-1080
cells. As the concentration of MG132 was increased to 10 Ǻ M, the ex-
pression of pro-caspase-8 and pro-caspase-3 fell (Fig. 3A).
Mitochondria-dependent apoptosis through activation of pro-
apoptotic BCL-2 family members such as BID and BAX is another
important apoptotic pathway. Cleavage of the pro-apoptotic BCL-2
family protein BID by caspase-8 is required for apoptosis in some cells
[9,10,16,17]. Activated truncated BID causes mitochondrial damage,
and therefore acts as an amplifying signal that links the extrinsic to the
intrinsic apoptotic death pathways. MG132 had shown various effects
in the expression of BID in STS cell lines, but it had little effect on the
expression of BID in HTB-82 and HTB-94 cell lines. MG132 caused a
dose-dependent decrease in the expression of BID in HT-1080 cells. It
induced a rise in BID expression at 1 Ǻ M and a fall at 10 Ǻ M in HTB-
93 cells. As the concentration of MG132 was increased in all four STS
cell lines (Fig. 3A) BAX expression was increased. 
Discussion 
Promising results from the introduction of high-dose TNF for
treatment of STS [18] has led to a large phase II multicenter study that
demonstrated the efficacy of this approach. However, because of
severe systemic toxicity, TNF-ǯadministration could be performed
only via isolated limb perfusion. Similarly, the therapeutic usefulness
of FasL was hampered by Fas expression on hepatocytes, resulting in
lethal hepatic apoptosis upon intravenous FasL administration [19]. In
contrast to TNF and FasL, TRAIL selectively promotes apoptosis in
cancer cells that express death receptors, and has little or no effect on
normal cells [3]. In addition, it has been shown that TRAIL-induced
apoptosis in a variety of tumor cells is augmented by combining
TRAIL with proteasome inhibitors. The mechanisms by which
proteasome inhibitors sensitize cells to TRAIL-induced apoptosis
appear to differ among cell types, but involve an increase in caspase-8
activation, with or without a decrease in the level of c-FLIP; an
increase in the levels of BH3-only pro-apoptotic BCL-2 proteins, such
as BIK and BIM; and inhibition of nuclear factor-Ш B activation [20].
In the present report, we show that TRAIL sensitivity varies among
different STS cell lines, and demonstrate that a combination of TRAIL
and the proteasome inhibitor MG132 can overcame TRAIL resistance,
augmenting the apoptotic activity of TRAIL. 
Although TRAIL receptor expression was different in the various
STS cell lines studied, it is difficult to define TRAIL sensitivity accor-
ding to TRAIL-receptor expression. Recent studies have demonstrated
that activation of either of the two caspase-coupled TRAIL receptors,
DR4 or DR5, is sufficient to fully trigger the apoptotic machinery of
the cell [21]. An increase in DR5 expression in response to a
proteasome inhibitor and chemotherapy has been reported, suggesting
that DR5 could also be a crucial contributor to the sensitization of cells
to TRAIL [15]. The notion that an increased ability to induce apoptosis
of cancer cells is of key importance in sensitization is highlighted by
the results described here using TRAIL/MG132 combination therapy.
The data showed that combined treatment enhanced induction of
apoptosis in both TRAIL-resistant and -sensitive STS cells. As shown
in Fig. 3, enhanced apoptosis was mediated through upregulation of
TRAIL receptors at both the whole-cell and surface-expression levels,
resulting in increased caspase-8 activation in some STS cells and BAX
activation in other STS cells. This finding suggests that MG132
upregulated TRAIL receptors and activated the mitochondrial pathway
through BAX activation. In addition, as its concentration increases,
MG132 may promote an amplification loop, in which activation of the
extrinsic apoptotic pathway enhances activation of the mitochondrial
apoptotic pathway. Although our studies did not directly address the
mechanism by which the proteasome inhibitor, MG132, increased the
expression of DR4 and DR5, previous reports have shown that pro-
teasome inhibitors increase DR5 transcriptional levels [15] via reactive
oxygen species-mediated p53 activation, which enhances binding of
p53 to the DR5 intron [22]. The broad-spectrum irreversible caspase
inhibitor z-VAD-fmk attenuated apoptosis induced by combined
treatment with TRAIL and MG132 in all four cells lines; however, the
caspase-8 inhibitor, z-IETD-fmk, showed differential effects.
Apoptosis induced by combined treatment with TRAIL and MG132
was largely unaffected by z-IETD-fmk in HTB-93 and HT-1080 cells,
but was influenced to a greater extent in HTB-82 and HTB 94 cells.
This difference might be attributable to differences in BID expression.
In HTB-93 and HT-1080 cells, higher concentrations of MG132
induced a decrease in BID expression, whereas BID expression wasCancer Res Treat. 2011;43(2):124-130
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unchanged in HTB 82 and HTB-94 cells. 
In some STS cells, MG132 restored TRAIL sensitivity through up-
regulation of TRAIL receptors, whereas in other cells TRAIL
resistance was overcome through activation of the mitochondrial
pathway by BAX. Thus, the combination of TRAIL and the protea-
some inhibitor, MG132, could affect both extrinsic and intrinsic
apoptotic pathways. 
Conclusion
In this study, we have investigated the effects of TRAIL and
MG132 on STS cell lines in vitro. Such cells exhibited differential sen-
sitivity to TRAIL, but there was no correlation between TRAIL sensi-
tivity and TRAIL receptor expression levels. Combining MG132 with
TRAIL enhanced apoptosis and overcame TRAIL resistance. This re-
storation of TRAIL sensitivity occurred through increases in expre-
ssion of TRAIL receptors and in BAX, a pro-apoptotic BCL-2 family
member. 
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